---
layout: default
title: Caffeine
parent: Model Prediction Only (L5)
nav_order: 130
evidence_level: L5
indication_count: 8
monitor_inn: "Caffeine"
predicted_indications: ["nasal cavity disease", "thrombotic disease", "papillary conjunctivitis", "neuralgia", "glossodynia", "coccygodynia", "trigeminal autonomic cephalalgia", "vein disease"]
last_modified_at: 2026-10-30
description: "Caffeine: predicted new indication nasal cavity disease (evidence level L5). Approved use: Not recorded in the local data"
---

# Caffeine
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **8** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist" markdown="1">

## Pharmacist Assessment Report

</div>

## Caffeine: adenosine receptor antagonist and phosphodiesterase inhibitor → nasal cavity disease
{: .text-alpha }

## One-Sentence Summary

Caffeine is a methylxanthine stimulant that blocks adenosine receptors and inhibits phosphodiesterase, and it is marketed in India in oral tablet products.
The TxGNN model predicts it may be relevant for **nasal cavity disease**, but the data compiled for this report contain **no clinical trials** and only **3 publications**, none of which studies a nasal disease directly.
This is a computational prediction with very limited supporting evidence.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | nasal cavity disease |
| TxGNN Prediction Score | 0.9991 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Registrations | at least 20 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Caffeine antagonizes adenosine receptors and inhibits phosphodiesterase. Detailed mechanism-of-action data were not available in the compiled data, so this description comes from general pharmacology and from the rationale compiled for this prediction.

One review describes bitter taste receptors in human airway tissue, including the nasal cavity, where they may modulate innate defense. This gives caffeine a plausible, though indirect, mechanistic link to nasal tissue.

The link remains speculative. The only nasal-specific paper concerns an intranasal caffeine gel designed to improve cognition after sleep deprivation. That is a drug-delivery study in a non-disease setting, not a treatment study for a nasal disease. Because no study directly addresses a nasal cavity disease, the evidence level is L5 (model prediction only).

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [26272040](https://pubmed.ncbi.nlm.nih.gov/26272040/) | 2015 | Review | Pharmacology & Therapeutics | Bitter taste receptors are found in airway tissues including the nasal cavity and may contribute to airway defense |
| [35579146](https://pubmed.ncbi.nlm.nih.gov/35579146/) | 2022 | Preclinical/formulation study | Current Drug Delivery | Thermo-sensitive intranasal caffeine gel developed to enhance cognition after sleep deprivation; not a nasal disease study |
| [9751618](https://pubmed.ncbi.nlm.nih.gov/9751618/) | 1998 | Animal study | Cancer Research | Black tea and caffeine reduced NNK-induced lung tumours in rats; not relevant to nasal disease |

---

## India Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 209998 | Snokey Cold Plus Tablet | strip of 10 tablets | Not recorded |
| 202438 | Signcold Tablet | strip of 10 tablets | Not recorded |
| 150830 | NT Grain Tablet | strip of 10 tablets | Not recorded |
| 235665 | Vinoryl Tablet | strip of 10 tablets | Not recorded |
| 144331 | Makzine P Tablet | strip of 10 tablets | Not recorded |

At least 20 valid registrations are on record, and this list may be partial. Only the first five are shown.

---

## Safety Considerations

- **Drug Interactions**: 75 interactions were found in total. Notable examples:
  - **Major**: cocaine (nasal) and cocaine (topical)
  - **Moderate**: alosetron, obeticholic acid, adenosine, anagrelide, bendamustine, capmatinib, ciprofloxacin, cycloserine, dipyridamole, duloxetine

Package insert warnings and contraindications were not available. Please refer to the package insert for full safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction score is high (0.9991), but there are no clinical trials and no published study of caffeine in a nasal disease. The available literature is a general review, a formulation study for a different purpose, and an unrelated animal study. Evidence is therefore limited to the model prediction.

**To proceed, the following is needed:**
- Clarification of which specific nasal disease is meant by "nasal cavity disease"
- Preclinical or clinical studies of caffeine in that specific condition
- Detailed mechanism of action data
- Package insert warnings and contraindications for a full safety review
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

